Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Darolutamide Linked to Better Real‑World Outcomes than Enzalutamide or Apalutamide in nmCRPC March 18, 2026
- AI CellVoyager Agent Turns Single‑Cell RNA‑seq Data into Continuous Hypothesis Generation March 18, 2026
- Ferroptosis-Nanoparticles Turn Prostate Tumors Hot: Docetaxel + Light Wakes Immunity March 18, 2026
- SonoPIN: Ultrasound‑Guided Microbubbles Deliver Large Cancer Drugs with Pinpoint Precision March 18, 2026

Androgen Receptor Inhibition Enhances Immune Response in Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxThe Phase 1 ACCEL Trial: Actinium-225-PSMA-62
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 3 Trial of TLX591 Kicks Off in Miami
/in Clinical Trial, Metastatic, Phase 3/by MaxCancer Vaccine? Yes, Universal Please…
/in Immunotherapy, Preclinical Research/by MaxGoogle’s AI Co-Scientist: A Leap Forward in Biomedical Research
/in Artificial Intelligence/by MaxOncoACP3: A Potential Game-Changer in Prostate Cancer Theranostics —Why?
/in Clinical Trial, Metastatic, Phase 1/by MaxEVO 2 AI: Redefining Genetic Engineering
/in Artificial Intelligence/by MaxENV105 to Reverse Resistance to ADT and ARSI
/in Clinical Trial, Metastatic, Phase 2/by Max